STAR Strides Pharma Science Q4 FY25 results (Jan–Mar 2025) and concall
Strides Pharma delivered a strong Q4 and FY25, exceeding guidance on revenue, EBITDA, and US sales. The company demonstrated significant operating leverage, leading to a 12x growth in operational PAT and an improved Net Debt to EBITDA ratio of 1.9x. A dividend of INR 4 per share was approved, reflecting robust financial performance and a focus on shareholder returns, despite some uncertainties regarding US tariffs and slight degrowth in access markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 520 | 551 | 556 |
| EBITDA | 55 | 74 | 68 |
| Net profit | 17 | 15 | 16 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
